Proteinuria

CSL Vifor and Travere Therapeutics acknowledge the updated KDIGO 2025 guidelines for IgA Nephropathy (IgAN). These guidelines refine diagnostic criteria, treatment goals, and therapeutic approaches for this leading cause of kidney failure. Notably, FILSPARI® (sparsentan), a Dual Endothelin Angiotensin Receptor Antagonist (DEARA), is highlighted as a potential first-line treatment option for managing IgAN-induced nephron loss, contrasting the traditional RASi-first approach. The guidelines cite the PROTECT trial, demonstrating FILSPARI’s efficacy compared to optimized RASi therapy. Experts believe the updated guidance will improve treatment decisions and long-term kidney outcomes.